Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RGNX 
Regenxbio Inc (RGNX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: RGNX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $29.75
1 Year Target Price $29.75
| 6 | Strong Buy |
| 5 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -45.15% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 455.13M USD | Price to earnings Ratio - | 1Y Target Price 29.75 |
Price to earnings Ratio - | 1Y Target Price 29.75 | ||
Volume (30-day avg) 12 | Beta 1.11 | 52 Weeks Range 5.04 - 13.48 | Updated Date 08/29/2025 |
52 Weeks Range 5.04 - 13.48 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.44 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.94 | Actual -1.38 |
Profitability
Profit Margin -112.7% | Operating Margin (TTM) -296.26% |
Management Effectiveness
Return on Assets (TTM) -17.89% | Return on Equity (TTM) -62.49% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 209531086 | Price to Sales(TTM) 2.92 |
Enterprise Value 209531086 | Price to Sales(TTM) 2.92 | ||
Enterprise Value to Revenue 1.34 | Enterprise Value to EBITDA -3.37 | Shares Outstanding 50514200 | Shares Floating 41423173 |
Shares Outstanding 50514200 | Shares Floating 41423173 | ||
Percent Insiders 7.66 | Percent Institutions 87.45 |
Upturn AI SWOT
Regenxbio Inc
Company Overview
History and Background
REGENXBIO Inc. was founded in 2009 and focuses on developing gene therapy products based on its NAV Technology Platform. The company aims to provide potentially curative treatments for serious genetic diseases.
Core Business Areas
- Gene Therapy Development: Development and commercialization of gene therapy products targeting various diseases.
- NAV Technology Platform: Licensing and utilizing its proprietary adeno-associated virus (AAV) vector technology for gene delivery.
Leadership and Structure
Kenneth T. Mills is the President and Chief Executive Officer. The company has a structured management team overseeing research and development, clinical trials, and commercialization efforts.
Top Products and Market Share
Key Offerings
- ABECMA (idecabtagene vicleucel): Licensed to Bristol Myers Squibb (BMY), ABECMA is a CAR-T cell therapy for multiple myeloma. REGENXBIO receives royalties on net sales. BMY and Johnson & Johnson are competitors in this space. Revenue based on Royalty percentages.
- RGX-314: An investigational gene therapy for wet age-related macular degeneration (AMD). Aims to provide a one-time treatment with sustained therapeutic effect. Competitors include Regeneron (REGN) and Roche (RHHBY). Market Share is currently non-applicable as it is in the clinical trials stage.
Market Dynamics
Industry Overview
The gene therapy market is rapidly growing, driven by technological advancements and increasing success rates in clinical trials. The market is driven by the increasing incidence of genetic disorders, technological advancements in gene therapy, and rising investments in R&D.
Positioning
REGENXBIO is positioned as a leader in AAV-based gene therapy, leveraging its NAV Technology Platform. Its competitive advantage lies in the breadth and depth of its vector library and its strategic partnerships.
Total Addressable Market (TAM)
The gene therapy market is projected to reach billions of dollars. REGENXBIO's positioning in AAV-based therapies gives it access to a significant portion of this TAM, especially in Ophthalmology and Neurodegenerative diseases.
Upturn SWOT Analysis
Strengths
- Proprietary NAV Technology Platform
- Strong intellectual property portfolio
- Strategic partnerships with major pharmaceutical companies
- Experienced management team
- Diverse pipeline of gene therapy candidates
Weaknesses
- Dependence on partners for commercialization
- Clinical trial risks and regulatory hurdles
- High R&D expenses
- Limited product revenue currently
Opportunities
- Expanding pipeline into new therapeutic areas
- Securing regulatory approvals for lead product candidates
- Further developing NAV Technology Platform
- Exploring new strategic partnerships
Threats
- Competition from other gene therapy companies
- Changes in regulatory landscape
- Adverse clinical trial results
- Patent challenges
Competitors and Market Share
Key Competitors
- BMY
- REGN
- SNY
- VRTX
- BLUE
Competitive Landscape
REGENXBIO is competing in a competitive gene therapy market. Its NAV Technology Platform provides a potential advantage, but success depends on clinical trial results and commercialization.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by advances in gene therapy and partnerships.
Future Projections: Analyst estimates predict growth based on successful clinical trial outcomes and potential commercialization of key product candidates.
Recent Initiatives: Focus on advancing RGX-314 and expanding the pipeline with new gene therapy programs.
Summary
REGENXBIO is a gene therapy company with a promising technology platform and a diverse pipeline. Success hinges on the clinical progress of its lead product candidates and securing regulatory approvals. They need to carefully navigate the competitive landscape and manage its financial resources effectively to achieve long-term success. Securing future milestones and partnerships are crucial for sustained growth. The main product candidate of focus is RGX-314.
Peer Comparison
Sources and Disclaimers
Data Sources:
- REGENXBIO Investor Relations
- SEC Filings
- Analyst Reports
- Company Website
Disclaimers:
The analysis is based on available data and current market conditions. Investment decisions should be made with careful consideration of individual risk tolerance and financial situation.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Regenxbio Inc
Exchange NASDAQ | Headquaters Rockville, MD, United States | ||
IPO Launch date 2015-09-17 | President, CEO & Director Mr. Curran M. Simpson M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 353 | Website https://www.regenxbio.com |
Full time employees 353 | Website https://www.regenxbio.com | ||
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.